AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(From Chemical Business NewsBase - Press Release)
Proteolix Inc announced the completion of a $45 M Series B financing. The new capital will be used to expand the company's on-going clinical trials of the novel proteasome inhibitor PR-171 in cancer and support the development of its pipeline. The financing was led by Delphi Ventures. Also …